Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Aug 14, 2025
DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025
Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued Enrollment
Multiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting Contraception
Four Commercially Available Solutions for Women on the Horizon
